SCHEMBL24793474

SCHEMBL24793474

O[C@H]1CNCC[C@@H]1CNc1cc(NCc2ccc(-c3ccccc3)cc2)n2ncc(C3CC3)c2n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK7 P50613 12/20 0.70
▸ CDK2 P24941 9/20 0.70
▸ CCNE1 P24864 7/20 0.70
▸ CCNH P51946 7/20 0.70
▸ MNAT1 P51948 7/20 0.70
▸ CDK1 P06493 6/20 0.70
▸ CDK4 P11802 3/20 0.70
▸ CDK9 P50750 3/20 0.70
▸ CDK6 Q00534 3/20 0.70
▸ CDK5 Q00535 3/20 0.70
▸ CDK8 P49336 2/20 0.70
▸ CHEK1 O14757 2/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CCNA1 P78396 1/20 0.46
▸ GSK3B P49841 2/20 0.41
▸ IRAK4 Q9NWZ3 2/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20848289 0.95 CDK7 (0.77) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL30083625 0.91 CDK7 (0.64) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24791465 0.91 CDK7 (0.64) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24791462 0.91 CDK7 (0.63) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24792712 0.91 CDK2 (0.63) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24792804 0.91 CDK7 (0.60) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24793454 0.90 CDK7 (0.70) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24793438 0.89 CDK7 (0.59) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24792978 0.89 CDK7 (0.60) CDK7CDK2CCNE1CCNHMNAT1
SCHEMBL24793455 0.89 CDK2 (0.71) CDK7CDK2CCNE1CCNHMNAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2024-11-21 — — US disclosed
WO-2022263604-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2022-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383900-A1 SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE CDK3, CDK1, CDK2 CDK7 11/4885CDK2 3/4885CCNE1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback